 |
More than 25,000 Devices Implanted Worldwide from 2010-20251
ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, proudly marks the 15th anniversary of the groundbreaking WEBâ„¢ Aneurysm Embolization System. Since its introduction, the WEB device has transformed the treatment of wide-neck bifurcation aneurysms, offering physicians and patients a clinically proven, single-device solution – One and Done – with proven simplicity, proven safety and durability, proven for ruptured aneurysms* and proven innovation2-9. The WEB device was commercially launched in October 2010 after receiving its CE (Conformité Européenne) Mark in Europe. The first implant was performed by Prof. Joachim Klisch in Germany, paving the way for a new era in aneurysm treatment.
The WEB device has proven clinical data, supported by seven global Good Clinical Practice (GCP) studies2-8 and over 200 peer-reviewed publications. Over the past 15 years, this revolutionary technology has changed the paradigm for aneurysm treatment, providing a safe, effective alternative to traditional methods.
Carsten Schroeder, President and CEO of Terumo Neuro, commented on this significant milestone: "The WEB device has set a new standard in aneurysm treatment and has been instrumental in our mission to drive game-changing impact in neurovascular care. With 15 years of proven clinical success, WEB continues to advance patient outcomes, reducing the need for multiple devices and lengthy procedures. As we celebrate this achievement, we remain committed to innovating alongside leading physicians worldwide to shape the future of neurovascular care."
Transforming Aneurysm Treatment with the WEB Device
The WEB device is the world's first intrasaccular flow disruptor, designed to treat brain aneurysms from inside the aneurysm sac. Unlike traditional treatments for wide-neck bifurcation aneurysms that require stents and coils, this device minimizes the need for dual antiplatelet therapy, simplifying procedures and enhancing patient safety, with a single device. Key milestones and clinical highlights of Terumo Neuro's WEB embolization system include:
- Unparalleled Clinical Data: The WEB device has been studied in over 600 patients across seven GCP trials, accumulating more than 1,464 patient-years with zero recorded rebleeds in a WEB device-treated aneurysm.2-8
- Proven Long-Term Safety & Durability: The five-year follow-up data from the WEB-IT, WEBCAST and WEBCAST 2 trials reaffirmed the WEB system's sustained efficacy and safety, including 0% device-related morbidity and mortality.7,8
- Expanding Treatment Options: The introduction of the WEB 17 system, a lower profile system to treat smaller aneurysms, has further refined aneurysm treatment providing physicians with greater flexibility and precision for a wider range of cases.
The WEB device's continued evolution underscores Terumo Neuro's dedication to advancing neurovascular technology. With more than 25,000 patients treated with the WEB device worldwide, this intrasaccular device remains the trusted choice for physicians seeking a reliable, single-device solution for wide-neck bifurcation aneurysms.
About Terumo Neuro (Formerly MicroVention, Inc.)
We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information on Terumo Neuro, please visit www.terumoneuro.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for one hundred years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large. For full indications for use, visit: WEBâ„¢ Embolization System | Terumo Neuro
*Information provided may not represent the approved indication for use for each country/market. Please refer to the Instruction for Use (IFU) in the specific market/country that you are looking into.
References:
- Data on file, Terumo Neuro.
- Pierot L, Moret J, Barreau X, et al. Safety and efficacy of aneurysm treatment with WEB in the cumulative population of three prospective, multicenter series. J Neurointerv Surg. 2018;10(6):553-559.
- Arthur AS, Molyneux A, Coon AL, et al. The safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide-necked bifurcation aneurysms: final 12-month results of the pivotal WEB Intrasaccular Therapy (WEB-IT) Study. J Neurointerv Surg. 2019;11(9):924-930.
- Pierot L, Moret J, Turjman F, Herbreteau D, et al. WEB Treatment of Intracranial Aneurysms: Clinical and Anatomic Results in the French Observatory. AJNR. 2016.
- Spelle, L., et al. (2022) "Clinical Assessment of WEB device in Ruptured Aneurysms (CLARYS): 12-month angiographic results of a multicenter study." J NeuroIntervent Surg.
- Spelle, L., et al. (2024) "Clinical Evaluation of WEB 17 device in intracranial aneurysms (CLEVER): 1-year effectiveness results for ruptured and unruptured aneurysms." J NeuroIntervent Surg.
- Pierot L, Szikora I, Barreau X, et al. Aneurysm treatment with the Woven EndoBridge (WEB) device in the combined population of two prospective, multicenter series: 5-year follow-up. J Neurointerv Surg. 2023;15(6):552-557.
- Fiorella D, Molyneux A, Coon A, et al. Safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide necked bifurcation aneurysms: final 5 year results of the pivotal WEB Intra-saccular. Therapy study (WEB-IT). J Neurointerv Surg. 2023;15(12):1175-1180.
- Rai AT, Turner RC, Brotman RG, Boo S. Comparison of operating room variables, radiation exposure and implant costs for WEB versus stent assisted coiling for treatment of wide neck bifurcation aneurysms. Interv Neuroradiol. 2021;27(4):465-472.
WEBâ„¢ is a trademark of MicroVention, Inc., registered in the United States and other jurisdictions. All brand names are trademarks or registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties. ©2024 MicroVention, Inc. MM2034(i) WW 03/25
Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+ 1 714 206 9800
christine.mccullough@microvention.com
More than 25,000 Devices Implanted Worldwide from 2010-20251
ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, proudly marks the 15th anniversary of the groundbreaking WEBâ„¢ Aneurysm Embolization System. Since its introduction, the WEB device has transformed the treatment of wide-neck bifurcation aneurysms, offering physicians and patients a clinically proven, single-device solution – One and Done – with proven simplicity, proven safety and durability, proven for ruptured aneurysms* and proven innovation2-9. The WEB device was commercially launched in October 2010 after receiving its CE (Conformité Européenne) Mark in Europe. The first implant was performed by Prof. Joachim Klisch in Germany, paving the way for a new era in aneurysm treatment.
The WEB device has proven clinical data, supported by seven global Good Clinical Practice (GCP) studies2-8 and over 200 peer-reviewed publications. Over the past 15 years, this revolutionary technology has changed the paradigm for aneurysm treatment, providing a safe, effective alternative to traditional methods.
Carsten Schroeder, President and CEO of Terumo Neuro, commented on this significant milestone: "The WEB device has set a new standard in aneurysm treatment and has been instrumental in our mission to drive game-changing impact in neurovascular care. With 15 years of proven clinical success, WEB continues to advance patient outcomes, reducing the need for multiple devices and lengthy procedures. As we celebrate this achievement, we remain committed to innovating alongside leading physicians worldwide to shape the future of neurovascular care."
Transforming Aneurysm Treatment with the WEB Device
The WEB device is the world's first intrasaccular flow disruptor, designed to treat brain aneurysms from inside the aneurysm sac. Unlike traditional treatments for wide-neck bifurcation aneurysms that require stents and coils, this device minimizes the need for dual antiplatelet therapy, simplifying procedures and enhancing patient safety, with a single device. Key milestones and clinical highlights of Terumo Neuro's WEB embolization system include:
- Unparalleled Clinical Data: The WEB device has been studied in over 600 patients across seven GCP trials, accumulating more than 1,464 patient-years with zero recorded rebleeds in a WEB device-treated aneurysm.2-8
- Proven Long-Term Safety & Durability: The five-year follow-up data from the WEB-IT, WEBCAST and WEBCAST 2 trials reaffirmed the WEB system's sustained efficacy and safety, including 0% device-related morbidity and mortality.7,8
- Expanding Treatment Options: The introduction of the WEB 17 system, a lower profile system to treat smaller aneurysms, has further refined aneurysm treatment providing physicians with greater flexibility and precision for a wider range of cases.
The WEB device's continued evolution underscores Terumo Neuro's dedication to advancing neurovascular technology. With more than 25,000 patients treated with the WEB device worldwide, this intrasaccular device remains the trusted choice for physicians seeking a reliable, single-device solution for wide-neck bifurcation aneurysms.
About Terumo Neuro (Formerly MicroVention, Inc.)
We are in business to create and deliver Game-changing Impact™—innovations that redefine what is possible in neuroendovascular treatment to meaningfully advance both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information on Terumo Neuro, please visit www.terumoneuro.com.
About Terumo Corporation
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for one hundred years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large. For full indications for use, visit: WEBâ„¢ Embolization System | Terumo Neuro
*Information provided may not represent the approved indication for use for each country/market. Please refer to the Instruction for Use (IFU) in the specific market/country that you are looking into.
References:
WEBâ„¢ is a trademark of MicroVention, Inc., registered in the United States and other jurisdictions. All brand names are trademarks or registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties. ©2024 MicroVention, Inc. MM2034(i) WW 03/25
Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+ 1 714 206 9800
christine.mccullough@microvention.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Terumo Neuro Celebrates 15 Years of the WEB™ Device: A Game-Changing Innovation in Aneurysm Treatment
DUBAI, UAE, Dec. 17, 2025 /PRNewswire/ -- Mantle, the high-performance distribution and liquidity layer connecting TradFi and on-chain finance, announced the End-of-Year edition of its monthly livestream series, featuring both a global session on December 18 and a China-focused builder livestream on December 19. The series reflects Mantle's focus on ecosystem growth, real-world assets (RWAs), and long-term builder support.
As Mantle's largest livestream to date, Episode 04 convenes 10+ industry leaders, builders, and ecosystem partners to reflect on Mantle's 2025 "MoMNTum" and explore what lies ahead across real-world assets (RWAs), builder infrastructure, and ecosystem growth. The episode marks Mantle's final community-facing broadcast of the year, bringing together perspectives from infrastructure providers, hackathon partners, and community content creators.
Reviewing a Year of MoMNTum
The livestream opens with 2025 Mantle Year in MoMNTum Review, highlighting key milestones across Mantle Network, ecosystem adoption, institutional alignment, and community growth over the past year. The session offers a consolidated view of how Mantle's distribution-layer strategy has progressed in practice.
A Sweet Home for RWAs
A core segment of the episode focuses on Mantle's expanding role as a home for real-world assets on-chain, featuring leaders actively building RWA infrastructure with Co-Founder from USDT0, Co-Founder from CIAN protocol, Business Development Lead from RedStone, Ecosystem & Partnership Lead from Mantle. Together, the panel will share insights on how RWAs are being structured, secured, and distributed on-chain, and how Mantle's architecture supports scalable, institution-ready deployment.
Mantle Global Hackathon & Scholar Reunion
Mantle's first global hackathon is spotlighted with contributions from OpenBuild and HackQuest, sharing how Mantle supports builders from onboarding to post-hackathon growth. The Mantle Scholar Reunion features community contributors reflecting Mantle's community-driven ecosystem.
Bybit 7th Anniversary & Community Rewards
As part of the End-of-Year edition, Bybit joins the livestream to provide a data-driven recap of the Bybit × Mantle partnership, covering key ecosystem metrics such as $MNT trading activity, holder growth, and user participation across the platform. Bybit's Senior Global Campaign Manager will also outline Mantle-themed initiatives launched as part of Bybit's 7th Anniversary, highlighting ongoing campaigns and engagement programs available to $MNT holders. The discussion will offer insight into how exchange-led activations support ecosystem growth and align with Mantle's broader distribution strategy.
To mark the End-of-Year livestream, Mantle will additionally host a POAP event with up to $1,000 USD in rewards for participating viewers, reinforcing Mantle's commitment to rewarding long-term community participation and closing the year with a community-first celebration.
China Livestream: Hackathon Builder Spotlight
Following the global session, Mantle will host a dedicated Chinese-language livestream on December 19, designed to give hackathon projects greater exposure to the community and wider audience.
This builder-focused session will feature the following hackathon teams including Cicada — a leading on-chain asset management platform providing compliant tokenization and issuance solutions that bring real-world assets on-chain with a next gen yield distribution and liquidity design.
Vimix — a Mantle-based application-layer project that turns content remixing into a Web3 participation primitive, capturing how ideas are picked up, extended, and transformed into on-chain attention and value through an Attention Graph.
Insight —Insight is a community-driven emotional data collection and annotation platform that leverages Web3-native incentives to build high-quality sentiment datasets for AI and decentralized applications.
The session reflects Mantle's ongoing commitment to post-hackathon support, offering builders visibility, feedback, and sustained momentum beyond the competition.
About Mantle
Mantle positions itself as the premier distribution layer and gateway for institutions and TradFi to connect with on-chain liquidity and access real-world assets, powering how real-world finance flows.
With over $4B+ in community-owned assets, Mantle combines credibility, liquidity and scalability with institutional-grade infrastructure to support large-scale adoption. The ecosystem is anchored by $MNT within Bybit, and built out through core ecosystem projects like mETH, fBTC, MI4 and more. This is complemented by Mantle Network's partnerships with leading issuers and protocols such as Ethena USDe, Ondo USDY, OP-Succinct and EigenLayer.
For more information about Mantle, please visit: mantle.xyz
For more social updates, please follow: Mantle Official X & Mantle Community Channel
For media enquiries, please contact: contact@mantle.xyz
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open, and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit's Communities and Social Media
Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Mantle Hosts End-of-Year Livestream Mantle State of Mind Episode 04, Bringing Together RWA Leaders, Builders, and Global Ecosystem Partners
